Le produit candidat GI-5005 sur le VHC de GlobeImmune améliore la réponse virologique prolongée de 10 pour cent, s'avérant être le premier vaccin thérapeutique susceptible de s'attaquer au VHC
April 15, 2010 13:00 ET
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 15, 2010) -
GlobeImmune, Inc. a annoncé aujourd'hui les données de la phase finale 2b
du GI-5005, le produit candidat Tarmogen(r) expérimental de...
GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting
March 17, 2010 16:12 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - March 17, 2010) - GlobeImmune Inc. today announced that three abstracts related to GI-5005, the company's hepatitis C (HCV) product candidate, have been accepted...
GlobeImmune Announces $17.5 Million Series E Financing
January 19, 2010 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - January 19, 2010) - GlobeImmune Inc., a company developing novel
therapies for patients with cancer and infectious diseases, today announced
a Series E Preferred Stock...
GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15%
November 02, 2009 08:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 2, 2009) - GlobeImmune Inc. will present Phase 2b data
today at the 60th Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD)...
GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting
October 06, 2009 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - October 6, 2009) - GlobeImmune Inc. today announced that a late
breaking abstract related to GI-5005, its investigational hepatitis C virus
(HCV) product candidate, has...
GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
May 15, 2009 07:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO and SUMMIT, NJ--(Marketwire - May 15, 2009) - GlobeImmune, Inc. and Celgene
Corporation (NASDAQ: CELG) today announced a worldwide strategic
collaboration focused on the discovery,...
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 Percent in Phase 2 Clinical Trial
April 24, 2009 01:59 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - April 24, 2009) - Twelve-week Phase 2 clinical trial data show
that patients treated with GI-5005, GlobeImmune's targeted molecular
immunogen (Tarmogen®) for the...
GlobeImmune Initiates Phase 1 Clinical Trial With NCI in CEA Over-Expressing Cancers
April 16, 2009 08:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - April 16, 2009) - GlobeImmune, Inc. today announced the
initiation of a Phase 1 clinical trial to investigate the safety and
tolerability of a new Tarmogen, GI-6207, in...
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
November 01, 2008 11:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 1, 2008) - Four-week Phase 2 clinical trial data show
that GI-5005, GlobeImmune's hepatitis C virus (HCV) targeted molecular
immunogen (Tarmogen®), doubled...
GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to Be Highlighted at the AASLD President's Press Conference
October 28, 2008 08:00 ET
|
GlobeImmune Inc.
LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that
four-week data from the on-going Phase 2 clinical trial for GI-5005, the
Company's therapeutic vaccine...